CKD therapy stack rebuilt
SGLT2 inhibitors, finerenone, and GLP-1 mechanisms are rebuilding the chronic-kidney-disease therapy stack.
Chronic kidney disease has gone from a narrow stack of options to a layered therapy regimen across SGLT2 inhibitors, mineralocorticoid-receptor antagonists, and increasingly GLP-1 agents. The integration question - who manages it, when - is now the open one.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- SnapshotHFrEF therapy reference (2026)
- ExplainedWhat is heart failure?
- SnapshotType 1 diabetes therapy reference (2026)
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.